Tawaratsumida Hiroki, Setoguchi Takao, Arishima Yoshiya, Ohtsubo Hideo, Akimoto Masaki, Ishidou Yasuhiro, Nagano Satoshi, Taketomi Eiji, Sunahara Nobuhiko, Komiya Setsuro
Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
The Near-Future Locomotor Organ Medicine Creation Course (Kusunoki Kai), Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan.
BMC Res Notes. 2017 Dec 21;10(1):765. doi: 10.1186/s13104-017-3086-7.
Osteoporosis is a complication of rheumatoid arthritis. We examined the risk factors for bone loss in rheumatoid arthritis patients receiving biological disease-modifying anti-rheumatic drugs. Lumbar spine and femoral neck bone mineral density was measured at two time points in 153 patients with rheumatoid arthritis managed with biological disease-modifying anti-rheumatic drugs. We examined patients' variables to identify risk factors for least significant reduction of bone mineral density.
Least significant reduction of lumbar spine bone mineral density (≤ - 2.4%) was seen in 13.1% of patients. Least significant reduction of femoral neck bone mineral density (≤ - 1.9%) was seen in 34.0% of patients. Multiple logistic regression analysis showed that a risk factor for least significant reduction of the lumbar spine was high-dose methylprednisolone use. Multiple regression analysis showed that a risk factor for least significant reduction of the femoral neck was short disease duration. Our findings showed that a risk factor for femoral neck bone mineral density reduction was a short disease duration. These findings suggest that rheumatoid arthritis patients receiving treatment with biological disease-modifying anti-rheumatic drugs may benefit from earlier osteoporosis treatments to prevent femoral neck bone loss.
骨质疏松是类风湿关节炎的一种并发症。我们研究了接受生物性改善病情抗风湿药物治疗的类风湿关节炎患者骨质流失的风险因素。对153例接受生物性改善病情抗风湿药物治疗的类风湿关节炎患者在两个时间点测量了腰椎和股骨颈的骨密度。我们研究了患者的各项变量，以确定骨密度降低最不显著的风险因素。
13.1%的患者腰椎骨密度降低最不显著（≤ -2.4%）。34.0%的患者股骨颈骨密度降低最不显著（≤ -1.9%）。多因素logistic回归分析显示，腰椎骨密度降低最不显著的一个风险因素是使用高剂量甲基强的松龙。多因素回归分析显示，股骨颈骨密度降低最不显著的一个风险因素是病程短。我们的研究结果表明，股骨颈骨密度降低的一个风险因素是病程短。这些发现表明，接受生物性改善病情抗风湿药物治疗的类风湿关节炎患者可能会从早期骨质疏松治疗中获益，以预防股骨颈骨质流失。
